2,454 followers
Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. #lymphoma #lymsm https://t.co/DAVCTjywxj
Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway. #lymphoma #lymsm https://t.co/DAVCTjywxj
Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via ... - Dove Medical Press https://t.co/69kXp71AAz